Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, et al. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br J Cancer. 2022;126(3):430-439.

Nuovo GJ, Suster D, Tili E, Awad H, Magro C. A Standardization Protocol for the In Situ Detection of SARS-CoV2 RNA and Proteins. Appl Immunohistochem Mol Morphol. 2022;30(2):83-90.

Gondane A, Girmay S, Helevä A, Pallasaho S, Loda M, Itkonen HM. O-GlcNAc transferase couples MRE11 to transcriptionally active chromatin to suppress DNA damage. J Biomed Sci. 2022;29(1):13.

Karajannis MA, Li BK, Souweidane MM, Liechty B, Yao J, Benhamida JK, et al. YAP1-MAML2 fusion in a pediatric NF2-wildtype intraparenchymal brainstem schwannoma. Acta Neuropathol Commun. 2022;10(1):117.

Gómez-Salinero JM, Izzo F, Lin Y, Houghton S, Itkin T, Geng F, et al. Specification of fetal liver endothelial progenitors to functional zonated adult sinusoids requires c-Maf induction. Cell Stem Cell. 2022;29(4):593-609.e7.

Staats K, Sosa BR, Kuyl E-, Niu Y, Suhardi V, Turajane K, et al. Intermittent parathyroid hormone increases stability and improves osseointegration of initially unstable implants. Bone Joint Res. 2022;11(5):260-269.

Villalba JA, Hilburn CF, Garlin MA, Elliott GA, Li Y, Kunitoki K, et al. Vasculopathy and Increased Vascular Congestion in Fatal COVID-19 and Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2022;206(7):857-873.

Stenzl A, Sternberg CN, Ghith J, Serfass L, Schijvenaars BJ, Sboner A. Application of artificial intelligence to overcome clinical information overload in urological cancer. BJU Int. 2022;130(3):291-300.

Xu B, Saliba M, Alzumaili B, Alghamdi M, Lee N, Riaz N, et al. Prognostic impact of extranodal extension (ENE) in surgically managed treatment-naive HPV-positive oropharyngeal squamous cell carcinoma with nodal metastasis. Mod Pathol. 2022;35(11):1578-1586.

Tsui DC, Aisner D, Nijmeh H, Bao L, Menter A, D Camidge R. Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy. Clin Lung Cancer. 2022;23(2):e99-e103.